NASDAQ:VRAY - Viewray Stock Price, Forecast & News

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray Inc (NASDAQ:VRAY) released its earnings results on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business earned $20.90 million during the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The business's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.39) earnings per share. View Viewray's Earnings History.

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

Viewray will be holding an earnings conference call on Thursday, March 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Viewray issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17-17 million, compared to the consensus revenue estimate of $18.27 million.

9 Wall Street analysts have issued 1-year price objectives for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they expect Viewray's stock price to reach $6.44 in the next twelve months. This suggests a possible upside of 103.9% from the stock's current price. View Analyst Price Targets for Viewray.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

News coverage about VRAY stock has trended very positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viewray earned a news impact score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View News Stories for Viewray.

Some companies that are related to Viewray include Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Zynex (ZYXI), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Pieris Pharmaceuticals (PIRS), T2 Biosystems (TTOO), Zynerba Pharmaceuticals (ZYNE) and Cara Therapeutics (CARA).

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fosun International Ltd (23.96%), FMR LLC (21.79%), Artisan Partners Limited Partnership (6.09%), Broadfin Capital LLC (5.61%), Bamco Inc. NY (2.00%) and State Street Corp (1.43%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC, New York State Common Retirement Fund, UBS Asset Management Americas Inc., Artisan Partners Limited Partnership, Goldman Sachs Group Inc., Royce & Associates LP and Virtu Financial LLC. View Insider Buying and Selling for Viewray.

VRAY stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Fosun International Ltd, Broadfin Capital LLC, Bamco Inc. NY, Marshall Wace North America L.P., Driehaus Capital Management LLC, Candriam Luxembourg S.C.A. and Essex Investment Management Co. LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $3.16.

Viewray has a market capitalization of $314.14 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

The official website for Viewray is http://www.viewray.com/.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]